BioXcel Therapeutics, Inc. (BTAI) Revenue History
Annual and quarterly revenue from 2016 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
BTAI Revenue Growth
BTAI Revenue Analysis (2016–2024)
As of May 8, 2026, BioXcel Therapeutics, Inc. (BTAI) generated trailing twelve-month (TTM) revenue of $752,000, reflecting significant decline in growth of -54.2% year-over-year. The most recent quarter (Q3 2025) recorded $98,000 in revenue, down 18.3% sequentially.
Looking at the longer-term picture, BTAI's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $2.3 million in 2024, representing a new all-time high.
When compared to Healthcare sector peers including ACAD (+9.9% YoY), INVA (+13.6% YoY), and AXSM (+63.9% YoY), BTAI has underperformed the peer group in terms of revenue growth. Compare BTAI vs ACAD →
BTAI Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| BTAICurrent | $752,000 | -54.2% | - | -2967.6% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 CORT | $761M | +12.2% | +16.6% | 5.9% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% |
BTAI Historical Revenue Data (2016–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $2.3M | +64.2% | $123K | 5.4% | $-67,245,000 | -2967.6% |
| 2023 | $1.4M | +268.0% | $120K | 8.7% | $-171,782,000 | -12448.0% |
| 2022 | $375K | - | $355K | 94.7% | $-159,645,000 | -42572.0% |
| 2021 | $0 | - | $-297,000 | - | $-105,895,000 | - |
| 2020 | $0 | - | $0 | - | $-82,297,000 | - |
| 2019 | $0 | - | $-156,000 | - | $-33,601,000 | - |
| 2018 | $0 | - | $-17,000 | - | $-19,962,000 | - |
| 2017 | $0 | - | $-1,000 | - | $-4,537,000 | - |
| 2016 | $0 | - | $0 | - | $-2,120,000 | - |
See BTAI's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BTAI Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BTAI vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonBTAI — Frequently Asked Questions
Quick answers to the most common questions about buying BTAI stock.
Is BTAI's revenue growth accelerating or slowing?
BTAI revenue declined -54.2% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $752000.00. This reverses the prior growth trend.
What is BTAI's long-term revenue growth rate?
BioXcel Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -54.2% is below this long-term average.
How is BTAI's revenue distributed by segment?
BTAI reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2024 are available for download. Segment mix reveals concentration and diversification trends.